Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKU NASDAQ:HLVX NASDAQ:KALA NASDAQ:OPGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkumin$0.18$0.12▼$1.90$26.32M-0.721.38 million shs8.54 million shsHLVXHilleVax$2.09$2.09$1.34▼$2.17$104.79M0.77808,344 shs1.24 million shsKALAKALA BIO$18.62+9.5%$8.87$2.92▼$18.89$130.73M-1.82259,777 shs548,207 shsOPGNOpGen$2.58$0.00▼$0.00$1K-1.77596 shs9 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%HLVXHilleVax0.00%-0.48%+0.48%+12.97%+22.22%KALAKALA BIO0.00%+27.97%+130.73%+333.02%+209.82%OPGNOpGen0.00%0.00%0.00%-100.00%-100.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkumin$0.18$0.12▼$1.90$26.32M-0.721.38 million shs8.54 million shsHLVXHilleVax$2.09$2.09$1.34▼$2.17$104.79M0.77808,344 shs1.24 million shsKALAKALA BIO$18.62+9.5%$8.87$2.92▼$18.89$130.73M-1.82259,777 shs548,207 shsOPGNOpGen$2.58$0.00▼$0.00$1K-1.77596 shs9 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%HLVXHilleVax0.00%-0.48%+0.48%+12.97%+22.22%KALAKALA BIO0.00%+27.97%+130.73%+333.02%+209.82%OPGNOpGen0.00%0.00%0.00%-100.00%-100.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUAkumin 0.00N/AN/AN/AHLVXHilleVax 2.00Hold$2.00-4.31% DownsideKALAKALA BIO 3.20Buy$21.7516.81% UpsideOPGNOpGen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AKU, OPGN, KALA, and HLVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $33.009/8/2025KALAKALA BIOMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$30.009/3/2025KALAKALA BIOLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/8/2025HLVXHilleVaxZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUAkumin$749.63M0.00N/AN/A$1.24 per share0.00HLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/AKALAKALA BIO$3.89M33.60N/AN/A$2.02 per share9.22OPGNOpGen$2.67M0.00N/AN/A($11.55) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUAkumin-$156.76M-$2.52N/AN/AN/A-30.56%-167.86%-7.81%N/AHLVXHilleVax-$147.27M-$1.43N/AN/AN/AN/A-34.29%-28.50%11/6/2025 (Estimated)KALAKALA BIO-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%11/11/2025 (Estimated)OPGNOpGen-$32.67MN/A0.00N/AN/A-1,140.36%N/A-287.58%11/13/2025 (Estimated)Latest AKU, OPGN, KALA, and HLVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025KALAKALA BIO-$1.82-$1.71+$0.11-$1.71N/AN/A8/6/2025Q2 2025HLVXHilleVax-$0.14-$0.11+$0.03-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUAkuminN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUAkumin17.020.990.99HLVXHilleVaxN/A26.3926.39KALAKALA BIO3.192.102.10OPGNOpGenN/A5.455.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUAkumin36.10%HLVXHilleVax86.42%KALAKALA BIO24.61%OPGNOpGen2.68%Insider OwnershipCompanyInsider OwnershipAKUAkumin20.51%HLVXHilleVax24.90%KALAKALA BIO8.32%OPGNOpGen43.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUAkumin3,63191.17 million72.47 millionNot OptionableHLVXHilleVax2050.14 million37.66 millionNot OptionableKALAKALA BIO307.02 million6.44 millionNot OptionableOPGNOpGen10010.07 million4.70 millionNot OptionableAKU, OPGN, KALA, and HLVX HeadlinesRecent News About These CompaniesOpGen Delays Filing of Quarterly ReportAugust 14, 2025 | tipranks.comOpGen Forms Joint Venture with European BankMay 29, 2025 | tipranks.comOpGen Delays 10-Q Filing Amid Operational ChallengesMay 16, 2025 | tipranks.comOpGen Inc ziet aanzienlijke aankoop van aandelen door AEI Capital LtdDecember 11, 2024 | nl.investing.comOpGen Inc aandeelhouder AEI Capital Ltd verhoogt belang met aankoop van €1,9 biljoenDecember 10, 2024 | nl.investing.comOpGen Appoints New COO and Company SecretaryDecember 6, 2024 | tipranks.comOpGen (OTC:OPGN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comOPGN Stock Earnings: OpGen Reported Results for Q2 2024August 21, 2024 | investorplace.comOPGN Stock Earnings: OpGen Reported Results for Q1 2024July 8, 2024 | investorplace.comOPGN Stock Earnings: OpGen Meets Revenue for Q4 2023June 5, 2024 | investorplace.comOpgen Inc (NASDAQ:OPGN) stock Posted Gross Margin of 6.62 percent in Last Year: Is Justifiable?May 27, 2024 | bovnews.comBOpGen, Inc.: OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 25, 2024 | finanznachrichten.deOpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 24, 2024 | globenewswire.comOpGen to Execute 1-for-10 Reverse Stock SplitMay 16, 2024 | 360dx.com3OpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock SplitMay 16, 2024 | finanznachrichten.deOpGen Announced 1-for-10 Reverse Stock SplitMay 16, 2024 | globenewswire.comOpGen, Inc. (OPGN) stock price, news, quote & history – Yahoo FinanceMay 4, 2024 | uk.finance.yahoo.comOpGen, Inc.: OpGen Provides Update on Business Operations and Strategic OpportunitiesApril 30, 2024 | finanznachrichten.deOpGen Provides Update on Business Operations and Strategic OpportunitiesApril 29, 2024 | globenewswire.comOpGen CEO David Lazar buys additional shares worth $150kApril 27, 2024 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKU, OPGN, KALA, and HLVX Company DescriptionsAkumin NASDAQ:AKUAkumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.HilleVax NASDAQ:HLVX$2.09 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.09 0.00 (0.00%) As of 09/12/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.KALA BIO NASDAQ:KALA$18.62 +1.62 (+9.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$18.78 +0.16 (+0.86%) As of 09/12/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.OpGen NASDAQ:OPGNOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
